Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment

Carmen Tur, Mar Tintoré, Ángela Vidal-Jordana, Denis Bichuetti, Pablo Nieto González, María Jesús Arévalo, Georgina Arrambide, Elisenda Anglada, Ingrid Galán, Joaquín Castilló, Carlos Nos, Jordi Río, María Isabel Martín, Manuel Comabella, Jaume Sastre-Garriga and Xavier Montalban

PLOS ONE, 2013, vol. 8, issue 12, 1-

Abstract: Objective: We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance. Methods: From a total of 185 patients, 114 patients on NTZ as of July 2011 carried out a comprehensive survey. We obtained disease severity perception scores, personality traits’ scores, and risk-acceptance scores (RAS) so that higher RAS indicated higher risk acceptance. We recorded JC virus status (JCV+/-), prior immunosuppression, NTZ treatment duration, and clinical characteristics. NTZ patients were split into subgroups (A-E), depending on their individual PML risk. Some 22 MS patients on first-line drugs (DMD) acted as controls. Results: No differences between treatment groups were observed in disease severity perception and personality traits. RAS were higher in NTZ than in DMD patients (p

Date: 2013
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0082796 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 82796&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0082796

DOI: 10.1371/journal.pone.0082796

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().